#FDA Approval #Liechtenstein #Vaduz #Implantica #RefluxStop

Implantica's Q3 2025 Report: FDA Approval on the Horizon

Implantica, a leading medtech company, has recently published its interim report for Q3 2025, highlighting significant milestones as they move closer to securing FDA approval for their innovative product, RefluxStop®. The report emphasized the company's proactive approach and positive developments that indicate strong momentum towards market entry in the United States.

Positive FDA Feedback and Production Expansion

In the latest quarter, Implantica received favorable feedback from the FDA regarding the final PMA Module 3 submission for RefluxStop®. This crucial step signals that the company is on track to meet the regulatory requirements needed for FDA approval. To prepare for the anticipated demand following approval, Implantica has expanded its production capabilities by an additional 10,000 units of RefluxStop®.

Furthermore, the company has invested in two new production tools, one of which is strategically located in the United States to facilitate local manufacturing. This move not only showcases Implantica's commitment to scaling operations but also emphasizes its readiness to meet U.S. market demands swiftly.

Enthusiastic Reception at the American Foregut Society Meeting

The Q3 report also detailed the enthusiasm generated by RefluxStop® at the 2025 American Foregut Society (AFS) Annual Meeting. The product was a focal point during an intense clinical panel, attended by over 100 leading experts in the field. They discussed promising five-year outcomes stemming from pivotal studies, marking RefluxStop® as a key innovation in anti-reflux treatment.

The panel presented the largest real-world safety data available, covering 602 patients from 22 centers across Europe, garnering significant attention and engagement from U.S. surgeons who are keenly interested in the product’s potential benefits.

Clear Path to FDA Approval

Notably, post-report period developments include the completion of a 100-Day FDA meeting. During this session, Implantica received clarity on the final approval steps, confirming that the remaining PMA requirements are clear and manageable. Inspections conducted by the FDA, including Bioresearch Monitoring (BIMO) inspections of both Implantica and the study site, concluded without any major findings. This positive outcome reinforces confidence in the company’s operational integrity and regulatory compliance as they approach the final stages of approval.

Financial Performance Overview

The Q3 financial summary reveals net sales increased by 6%, amounting to TEUR 365, compared to TEUR 344 from the previous year. The adjusted gross margin slightly declined to 93% (from 97%), but commendably, the operating loss (EBIT) showed improvement, decreasing to TEUR 4,432 from TEUR 5,336. This trend of shrinking losses also extends to the company's after-tax figures, which fell to TEUR 4,415, down from TEUR 6,444.

Over the first nine months of the year, Implantica's performance indicated a steady growth trajectory, with net sales rising by 3% to TEUR 1,543. The adjusted gross margin remained robust at 94%, reflecting strong product demand.

Looking Ahead: Teleconference Details

To share insights and discuss these developments, Implantica has scheduled a teleconference on October 31, 2025, at 1500 CET. Key figures, including CEO Peter Forsell and CFO Andreas Öhrnberg, will provide further details on the financial results and the path forward for RefluxStop®.

Conclusion

The Q3 2025 report illustrates Implantica's strategic positioning in the medtech landscape as they near FDA approval for RefluxStop®. With robust sales figures and a clear path to market entry, Implantica appears well-prepared to make a significant impact in the anti-reflux treatment arena. As they continue to innovate and expand their operations, the industry eagerly anticipates the official launch of RefluxStop® in the U.S. market.

For additional information, or to access the teleconference, visit Implantica's official website.